Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 11/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.37 |
| ▸ | PRKACA | P17612 | 2/20 | 0.34 |
| ▸ | PRKACG | P22612 | 2/20 | 0.34 |
| ▸ | PRKACB | P22694 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25932798 | 1.00 | TDP1 (0.56) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25930625 | 1.00 | TDP1 (0.56) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23920928 | 0.92 | TDP1 (0.56) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25932868 | 0.92 | TDP1 (0.56) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23920995 | 0.91 | TDP1 (0.54) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25932924 | 0.91 | TDP1 (0.54) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25930826 | 0.91 | TDP1 (0.54) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25932847 | 0.91 | TDP1 (0.55) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25930742 | 0.91 | TDP1 (0.55) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25932906 | 0.90 | TDP1 (0.54) | TDP1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PRKAG3 | TDP1 669/4885PDE4A 11/4885PDE4B 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.